The FDA approved a high‑dose Wegovy injection (7.2 mg) for chronic weight management after an expedited review under the commissioner’s voucher program. Novo Nordisk received clearance roughly 54 days after filing, the company announced, adding a higher‑potency option to its GLP‑1 portfolio. Company statements tied the rapid review to a political arrangement: Novo had earlier agreed to price concessions with the U.S. administration to secure the voucher. Investors and competitors noted the move sharpens competition with Lilly’s obesity franchise and could affect market share and pricing dynamics. Regulatory observers flagged the voucher program’s short timelines and potential policy controversy as agencies weigh speed versus transparency. Clinicians say the new dose may provide another therapeutic intensity for patients but stressed the need for post‑marketing safety monitoring at higher exposures.